Md Ariful Haque

Nilotinib versus Imatinib for Newly Diagnosed Chronic Myeloid Leukemia

Giuseppe Saglio, Dong‐Wook Kim, Surapol Issaragrisil et al. · New England Journal of Medicine · 2010 · 1.7K citations · Full text

Medicine, Pharmacology, Pharmacotherapy +10

Nilotinib (formerly AMN107), a highly selective BCR-ABL tyrosine kinase inhibitor, is effective in patients with Philadelphia chromosome–positive chronic myelogenous leukemia in chronic phase following imatinib resistance and intolerance

Hagop M. Kantarjian, Francis J. Giles, Norbert Gattermann et al. · Blood · 2007 · 745 citations · Full text

Medicine, Oncology, Pharmacology +9

Impact of Baseline <i>BCR-ABL</i> Mutations on Response to Nilotinib in Patients With Chronic Myeloid Leukemia in Chronic Phase

Timothy P. Hughes, Giuseppe Saglio, Susan Branford et al. · Journal of Clinical Oncology · 2009 · 309 citations · Full text

Life Sciences, Oncology, Pharmacotherapy +14

Initial Molecular Response at 3 Months May Predict Both Response and Event-Free Survival at 24 Months in Imatinib-Resistant or -Intolerant Patients With Philadelphia Chromosome–Positive Chronic Myeloid Leukemia in Chronic Phase Treated With Nilotinib

Susan Branford, Dong‐Wook Kim, Simona Soverini et al. · Journal of Clinical Oncology · 2012 · 93 citations · Full text

Medicine, Hematology, Pharmacology +14

Financial threat, hardship and distress predict depression, anxiety and stress among the unemployed youths: A Bangladeshi multi-city study

Mohammed A. Mamun, Shaila Akter, Imran Hossain et al. · Journal of Affective Disorders · 2020 · 92 citations · Full text

Social Sciences, Psychiatry, Psychology +15